An interventional study of BQ 1.2 in Incomplete Spinal Cord Injury, sponsored by BrainQ Technologies Ltd.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-22.
Sponsored by BrainQ Technologies Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Paraplegia with a site in United States — 17 open to participants now, 18 under way, 2 of them phase 3. Paraplegia · United States.
Among the 64 studies in Paraplegia with a site in United States, this one is the 46th largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2019, is one of 37 with no phase, reaches primary completion later than 0 of the 17 other live ones, and was the 34th registered.
152 studies on the registry are indexed under Paraplegia; 37 are open to participants now.
Browse Paraplegia studies →17 of the 64 studies in Paraplegia with a site in United States are open now. Recruiting first, the newest first:
Northwell Health · Sites in United States
Ages 21–75
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
University of Maryland, Baltimore · Sites in United States
Ages 30–85
Elpida Therapeutics SPC · Sites in United States, Spain
Ages 4 mo–72 mo
Wandercraft · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 32 Paraplegia studies recruiting now, 15 (47%) set no upper age limit and 14 (44%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 11 · Phase 3 4
First in 2000; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 8 is below the median of 17 across 116 interventional studies indexed under Paraplegia.
Median enrollment 22 across the 54 interventional studies, 58 across the 10 observational. Of the 38 that completed or were terminated, 16 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 64 have an industry lead sponsor. The 10 most frequent:
BrainQ Technologies Ltd. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
BrainQ Technologies Ltd. has 1 study filed under Paraplegia — fewer than ten, so there is no comparison to draw.
7 of the studies in Paraplegia with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT06295146University of PittsburghVirtual Peer Coaching in Manual Wheelchair Skills | 2026-12-30 |
| NCT05626816MetroHealth Medical CenterAcute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury | 2026-12-31 |
| NCT05848271University of California, San DiegoNatural History Study of Patients with HPDL Mutations | 2026-12-31 |
| NCT03026816University of MinnesotaEpidural Stimulation After Neurologic Damage | 2027-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Paraplegia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to further establish safety and efficacy of the BQ EMF treatment of chronic SCI subjects who demonstrate stability in The Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP) strength score following a one-month physical therapy run-in period.
BQ is a brain-computer interface (BCI) based medical device that produces and delivers non-invasive, low intensity and low frequency electromagnetic fields targeting a patient's central nervous system (CNS) for motor rehabilitation. The technology behind the device utilizes machine learning (ML) tools to identify high-resolution spectral patterns, which characterize motor functions within EEG and MEG/EMG measurements taken during functional motor tasks. These patterns are then translated into a frequency-dependent, low intensity and non-invasive electromagnetic treatment, which applies similar patterns directly to a patient's CNS.
BQ treatment is intended to improve upper limb motor function of chronic SCI patients, over 18 years of age with an incomplete injury and upper limb motor impairment (AIS B - D, Cervical C1 - C8). The treatment will be administered as an adjunctive treatment along with a typical pharmacological and/or non-pharmacological treatment plan.
Study is a prospective, single arm, multicenter study with physical therapy (PT) run-in phase, where each subject serves as his/her own control. Study population will include at least 8 individuals with traumatic or (incident-related) non-traumatic chronic cervical incomplete SCI (AIS B-D) who are 12 - 30 months post-injury, with score between 5 - 35 on GRASSP strength subscore on at least one side, and medically stable.
The primary objective of this study is to evaluate the efficacy of the BQ system treatment in improving upper limb motor function of chronic SCI subjects, compared to their own baseline after stability has been demonstrated during physical therapy run-in period, as measured by improvement in GRASSP strength subscore. An additional secondary objective of the study is to evaluate the efficacy of the BQ system treatment in improving motor recovery, spasticity, pain, QOL, and imaging outcomes in the stated population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects not eligible for this study include those that have any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment group, to receive BQ treatment with PT, after stability established in 4 week PT run-in period
Device: BQ 1.2
BQ 1.2 exposure of EMF exposure paradigm in conjunction with upper limb PT regimen
Change from baseline of treatment to end of treatment in the Graded and Redefined Assessment of Strength, Sensibility and Prehension (GRASSP - strength subscore):
The GRASSP is a clinical measure of upper limb impairment, which incorporates the construct of upper limb sensorimotor function. This measurement captures information on upper limb sensorimotor impairment for individuals with tetraplegia and defines neurological status with numerical values, which represent the deficits in a predictive pattern. The GRASSP demonstrates reliability, construct validity, and concurrent validity for use as a standardized upper limb impairment measure for individuals with incomplete SCI (Kalsi-Ryan et al., 2012). Scores can be used to determine relationships between impairment and functional capability of the upper limb. The evaluation includes three domains of hand function: 1. Strength (primary) 2. Sensibility (secondary) 3. Prehension (secondary) For the primary outcome measure, only the strength subscore will be assessed as follows: ● Strength (10 muscles of arm \& hand): motor grade 0-5 for each (sum = subtest total, 0-50)
Time frame: Week 22
GRASSP (strength subscores)
The GRASSP is a clinical measure of upper limb impairment, which incorporates the construct of upper limb sensorimotor function. This measurement captures information on upper limb sensorimotor impairment for individuals with tetraplegia and defines neurological status with numerical values, which represent the deficits in a predictive pattern. The GRASSP demonstrates reliability, construct validity, and concurrent validity for use as a standardized upper limb impairment measure for individuals with incomplete SCI (Kalsi-Ryan et al., 2012). Scores can be used to determine relationships between impairment and functional capability of the upper limb. ● Strength (10 muscles of arm \& hand): motor grade 0-5 for each (sum = subtest total, 0-50)
Time frame: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
GRASSP (sensibility and prehension subscores)
For the secondary outcome measure, the sensibility and prehension subscores will be assessed as follows: * Dorsal sensation (3 locations): each scored 0-4 (sum = subtest score, 0-12) * Palmar sensation (3 locations): each scored 0-4 (sum = subtest score, 0-12) * Prehension ability: 3 grasps (cylindrical, lateral key, tip to tip), each scored 0-4 (sum = 0-12). * Prehension performance: 6 prehension tasks - pour water from bottle, pick up an object, transfer 9 pegs from board to board, screw four nuts onto bolts, each scored 0-5 (sum = subtest score, 0-30).
Time frame: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury)
This is a system of tests used to define and describe the extent and severity of a subject's spinal cord injury. The subject's grade is based on how much sensation he or she can feel at multiple points on the body, as well as tests of motor function. For the purposes of this study, only the motor subtests and functions (UEMS \& LEMS) will be considered as a secondary outcome measure. The full ISNCSCI will be administered and assessed at baseline and end of treatment only for AIS classification purposes.
Time frame: Week -1, week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
Modified Ashworth Scale (MAS)
The Modified Ashworth scale (MAS) measures resistance during passive soft-tissue stretching and is used as a simple measure of spasticity (Bohannon \& Smith, 1987). Scoring are as follows: * 0: No increase in muscle tone * 1: Slight increase in muscle tone, manifested by a catch and release or by minimal resistance at the end of the range of motion when the affected part(s) is moved in flexion or extension * 1+: Slight increase in muscle tone, manifested by a catch, followed by minimal resistance throughout the remainder (less than half) of the ROM * 2: More marked increase in muscle tone through most of the ROM, but affected part(s) easily moved * 3: Considerable increase in muscle tone, passive movement difficult * 4: Affected part(s) rigid in flexion or extension
Time frame: Week -1, week 1, week 5, week 22
Spinal Cord Independence Measure III (SCIM III - self-care sub-score)
The Spinal Cord Independence Measure (SCIM) is a disability profile containing 3 sub-scales developed specifically for people with spinal cord injury (SCI). Through measures across its distinct scales, the profile describes subjects' ability to undertake activities of daily living (Ackerman, Morrison, McDowell, \& Vazquez, 2010). Each area is scored according to its proportional weight in these subjects' general activity. The final score ranges from 0 to 100 (Ackerman et al., 2010). The SCIM includes the following areas of function: * Self-care (sub-score 0 - 20) * Respiration and sphincter management (sub-score 0 - 40) * Mobility (sub-score 0 - 40)
Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
Questionnaire of von Korff et al. Grading the Severity of Chronic Pain
This is a simple method of grading the severity of chronic pain. This questionnaire grades the severity of chronic pain based on its characteristics and its impact on a person's activities (Von Korff, Ormel, Keefe, \& Dworkin, 1992). Answers are graded on a 0 (no) - 10 (extreme) scale for each of the following questions: * Rate pain at present time * Rate of most intense pain in the last 6 months * Rate of average pain in the last 6 months * In the past 6 months, how has pain interfered with your daily activities * In the past 6 months, how has pain interfered with your recreational social and family activities * In the past 6 months, how has pain interfered with your ability to work
Time frame: Week 1, week 5, week 22
Capabilities of the Upper Extremity Test (CUE-T)
A 32-item questionnaire with items in seven domains. The CUE test displays excellent test/retest reliability, and excellent correlation with impairment and capacity measures in persons with incomplete SCI. Subjects are scored on a 7-point scale representing self-perceived difficulty: 1 indicating totally limited, can't do at all, and 7 indicating not at all limited. Minimum score is 32 and maximum score is 124 (Marino, Shea, \& Stineman, 1998). Subjects will be asked to complete the following tasks: * 15 unilateral (left and right) items * 2 bilateral items * 3 reaching items * 4 pulling/pushing items * 2 wrist items * 6 hand/finger items * 2 bilateral items
Time frame: Week 1, week 5, week 22
The Spinal Cord Injury-Quality of Life (SCI-QOL)
The measurement system was developed to address the shortage and non-uniformity of subject-reported outcome measures for clinical care and research in SCI rehabilitation. It consists of 19 items, measuring emotional health (depression, anxiety, resilience, positive affect and well-being, grief/loss, self-esteem, stigma, psychological trauma); physical-medical health (bowel management, bladder management, bladder complications, pressure ulcers, pain interference, pain behavior); social participation (ability to participate in social roles and activities, satisfaction with social roles and activities, independence); physical function (basic mobility, self-care, fine motor functioning, wheelchair mobility, ambulation) (Tulsky et al., 2015).
Time frame: Week 1, week 5, week 22
Magnetic Resonance Imaging (MRI) and Diffusion Tensor Imaging (DTI) scans
For applicable subjects, MRI scans will be performed, preferably with a 3.0 T Ingenia Philips scanner, according to the follow sequences: A. Sagittal T2 B. Sagittal STIR C. Sagittal PW (proton density) D. Sagittal T1 E. Sagittal DTI F. Axial T1 G. Axial T2 MRI results will be analyzed to quantify tissue integrity (e.g. white matter, grey matter, cerebrospinal fluid). DTI measurements will be used to identify water movement, which, in the CNS, is often localized within axons, and provides high contrast towards white matter, indicating the quality and quantity of nerve fibers. This endpoint is not obligatory per protocol; failure to complete in contraindicated subjects is not considered a protocol deviation per Good Clinical Practice.
Time frame: Week 5, week 22
Surface EEG
Surface EEG will be recorded throughout the trial to gauge subject progress. This endpoint is exploratory, and will not be used for diagnostic or inclusionary/exclusionary purposes.
Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26
Surface EMG
Surface EMG will be recorded throughout the trial to gauge subject progress. EMG will be recorded in a bipolar setting from electrode pairs on the following muscles: flexor carpi radialis brevis, extensor carpi radialis brevis, flexor carpi ulnaris, extensor carpi ulnaris. The subjects will be seated and requested to perform hand and arm movements, to their best ability, upon cues. This endpoint is exploratory, and will not be used for diagnostic or inclusionary/exclusionary purposes.
Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26
Smoothness of reaching movement
Upper extremity (UE) kinematics data will be collected using a motion capture system. Retro-reflective markers will be attached directly to the subject with use of double sided tape on the anatomical joint mark points using the modified Helen Hayes marker set (torso, head and upper extremity). All kinematic data will be collected and time matched with the EMG data and transferred to a custom MATLAB (Mathworks, Natick, MA) algorithm code for further analysis. Upper extremity joint kinematics, muscle activation (sEMG) and EEG data will be recorded during several activities. To evaluate the smoothness of movements, the third derivative of the UE joint angles will be computed and considered for estimation of smoothness at the shoulder, elbow and wrist joints.
Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
Range of motion (ROM)
Upper extremity (UE) ROM (in the sagittal, frontal, and transverse planes) will be collected using a motion capture system. Retro-reflective markers will be attached directly to the subject with use of double sided tape on the anatomical joint mark points using the modified Helen Hayes marker set (torso, head and upper extremity). Upper extremity ROM, muscle activation (sEMG) and EEG data will be recorded during several activities.
Time frame: Week 1, week 5, week 9, week 14, week 18, week 22, week 26, week 34
Venous blood collection
Five ml whole venous blood will be collected at baseline (W5), midterm (W14), at end of treatment phase (W22), and first follow-up (W26) from all subjects. Blood will be separated to two test tubes, 2.5 CC in each, one with anti-coagulant (EDTA) and one without. Red blood cells will be separated from plasma (EDTA tube, by centrifugation) or from serum by clotting. Plasma and serum samples will be frozen in 0.5 cc aliquots at -80°C. Samples will be analyzed for CNS insult biomarkers, including glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), as well as brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), and nerve growth factor beta (NGFβ). This draw is an exploratory endpoint, and is not obligatory PP if contraindicated.
Time frame: Week 1, week 5, week 22
Assessment of device's Usability by user (Human factors and usability analysis)
Usability form to be completed by device user (operator) shall include: 1. Subjective feedback questionnaire: Subjective feedback focusing on any concerns on using device, ease of use, and potential deviations from proper use. 2. Informative questions to ensure proper understanding and operation of the device. The form is designed in order to track possible deviations from required treatment due to human factors, as well as specific elements of the treatment which may pose a risk due to human factors and have not been accounted for in the design and validation process.
Time frame: Week 0 of 1st patient, week 22 of 2nd patient, week 34 of 4th patient
Rate of deviation of device user from expected input sequence (Human factors and usability analysis)
Deviation of device user from expected input sequence, defined as exiting the "treatment flow" during treatment or canceling treatment unnecessarily, and obtained by user activity logging. The expectation is that these deviations should occur in less than 10% of treatment sessions
Time frame: Week 34 of 4th patient
Plan to share: No — Metadata can be made available, upon reasonable request Individual patient data (IPD) to be shared if significant need/benefit can be demonstrated, and only with permission of individual subject, as it is not specifically covered in informed consent form (ICF)
No publications or documents are linked to this record.
Started Sep 2019 (actual). Primary completion is estimated for Dec 2023, 50 months after the start.
Of 60 interventional studies with no phase under Paraplegia, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 131. This study's planned 50 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BrainQ Technologies Ltd.